ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 04 Jun 2021 The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough. Find out more Show/Hide
ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation 07 Jun 2017 Results presented at the ASCO 2017 Annual Meeting in Chicago show olaparib delays progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients? Find out more Show/Hide
BRCA-targeting drug olaparib could offer hope for women with advanced breast cancer with inherited mutation 27 Feb 2017 AstraZeneca has issued a statement saying a phase III trial of the ovarian cancer drug olaparib significantly delayed progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients? Find out more Show/Hide